Pacira BioSciences, Inc.

Listed Company

PCRXCIK 0001396814NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$726.41M

Net Income

$7.03M

Total Assets

$1.26B

Equity

$693.11M

Shares Out

39.35M

Op. Cash Flow

$151.99M

Business

Pacira BioSciences, Inc. develops, manufactures and commercializes non‑opioid pain therapies and advanced local biological treatments. Its main products and candidates include EXPAREL (bupivacaine liposome injectable suspension), ZILRETTA (extended‑release intra‑articular corticosteroid), the iovera° handheld cryoanalgesia system, and PCRX‑201, a locally administered HCAd gene therapy candidate for osteoarthritis. The company operates through commercial product commercialization, clinical development of novel therapeutics and device innovation, and manufacturing and supply partnerships. Its products are primarily marketed and distributed in the U.S. through hospitals, ambulatory surgical centers, dental and physician offices and national wholesalers, with efforts to expand internationally via partners.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	726	701	675	667	542
Cost of goods sold	150	170	185	199	140
Research and development	117	82	76	85	56
Selling, general and administrative	369	294	269	255	199
Amortization of acquired intangible assets	57	57	57	57	14
Goodwill impairment	0	163	0	0	—
Contingent consideration gains, acquisition-related expenses, restructuring and other	14	8	−352,000	11	43
Total operating expenses	707	774	587	607	452
Income (loss) from operations	19	−73	88	60	90
Interest income	23	20	11	5	896,000
Interest expense	−17	−17	−20	−40	—
(Loss) gain on early extinguishment of debt	−983,000	8	−17	0	0
Other, net	−7	−373,000	−186,000	−11	−3
Total other (expense) income, net	−2	10	−26	−47	−34
Income (loss) before income taxes	17	−63	62	13	56
Income tax expense	−10	−36	−20	3	−14
Net income (loss)	7	−100	42	16	42
Basic net income (loss) per common share (in dollars per share)	0.16	−2.15	0.91	0.35	0.95
Diluted net income (loss) per common share (in dollars per share)	0.16	−2.15	0.89	0.34	0.92
Basic (in shares)	45	46	46	46	44
Diluted (in shares)	45	46	52	47	46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	159	277	153	104	586
Short-term available-for-sale investments	80	208	125	185	71
Accounts receivable, net	124	113	106	98	96
Inventories, net	153	125	104	96	99
Prepaid expenses and other current assets	33	22	22	15	15
Total current assets	548	745	510	498	866
Fixed assets, net	141	167	174	184	188
Right-of-use assets, net	42	49	61	71	76
Goodwill	20	0	163	163	145
Intangible assets, net	368	426	483	541	624
Deferred tax assets	124	130	144	160	153
Investments and other assets	22	36	36	27	22
Total assets	1,265	1,554	1,574	1,681	2,075
Accounts payable	15	19	16	15	11
Accrued expenses	96	80	64	90	128
Lease liabilities	10	9	9	9	8
Current portion of long-term debt, net	0	202	—	—	—
Total current liabilities	121	310	97	148	521
Long-term debt, net	372	384	—	—	—
Lease liabilities	36	45	55	65	72
Contingent consideration	18	20	25	28	58
Deferred tax liabilities	4	0	—	—	—
Other liabilities	21	17	14	10	20
Total liabilities	572	775	704	906	1,345
Commitments and contingencies (Note 20)	—	—	—	—	—
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, par value $0.001; 250,000,000 shares authorized; 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024	48,000	47,000	46,000	46,000	45,000
Treasury stock, at cost, inclusive of excise tax and broker fees, 6,774,038 and 837,240 shares at December 31, 2025 and 2024, respectively	−177	−25	0	—	—
Additional paid-in capital	1,065	1,009	977	924	942
Accumulated deficit	−199	−206	−107	−149	−212
Accumulated other comprehensive income	4	343,000	247,000	−380,000	167,000
Total stockholders equity	693	778	870	775	730
Total liabilities and stockholders equity	1,265	1,554	1,574	1,681	2,075

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Indefinite-lived intangible asset impairment	26	0	0	26	0
Investment impairment	11	0	0	10	0
Loss on lease terminations	0	2	0	0	—
Deferred taxes	6	21	16	—	—
Depreciation of fixed assets and amortization of intangible assets	91	79	76	92	29
Amortization of debt issuance costs and debt discount	3	3	4	—	—
Stock-based compensation	58	51	48	48	42
Changes in contingent consideration	−2	−4	−3	−29	−989,000
Net accretion of discount on available-for-sale investments	−5	−7	−5	—	—
Other net (gains) losses	−6	236,000	2	285,000	3
Accounts receivable, net	−11	−8	−7	−2	−10
Inventories, net	−28	−21	−8	2	−4
Prepaid expenses and other assets	−1	61,000	−5	−3	1
Accounts payable	−6	3	916,000	6	−10
Accrued expenses and other liabilities	7	14	−22	—	—
Net cash provided by operating activities	152	189	155	145	126
Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)	−17	0	0	0	−420
Purchases of fixed assets	−15	−11	−15	−30	−46
Purchases of available-for-sale investments	−141	−252	−138	−388	−611
Sales of available-for-sale investments	274	180	237	238	1,069
Purchases of debt and equity investments	−1	0	−7	−13	−17
Net cash provided by (used in) investing activities	99	−83	78	−225	−21
Proceeds from exercises of stock options	502,000	0	2	24	24
Proceeds from shares issued under employee stock purchase plan	3	2	3	—	—
Payment of employee withholding taxes on restricted stock unit vests	−6	−491,000	−106,000	0	0
Purchase of treasury stock, inclusive of broker fees	−148	−25	0	0	—
Proceeds from Revolving Credit Facility	101	0	0	0	364
Proceeds from 2029 convertible senior notes	0	288	0	0	—
Proceeds from Term loan A facility	0	0	150	—	—
Repayment of Revolving Credit Facility	−10	0	0	—	—
Purchase of capped call transactions	0	−27	0	0	—
Debt extinguishment costs	0	0	−6	0	0
Payment of debt issuance and financing costs	−2	−9	−1	−1	−5
Net cash (used in) provided by financing activities	−370	17	−183	−402	381
Effect of exchange rate changes on cash and cash equivalents	−77,000	0	0	—	—
Net (decrease) increase in cash and cash equivalents	−118	123	49	−481	486
Cash paid for interest	15	15	28	33	7
Fixed assets included in accounts payable and accrued liabilities	1	6	2	6	7
Share repurchases included in accrued liabilities	2	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro